FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Rode

Research Profile

Chemicals & Drugs

Disorders

HIV Infections

Living Beings

HIV-1

Concepts & Ideas

Procedures

Physiology

Viral Drug Resistance

Activities & Behaviors

Patient Compliance

Co-author Network

Publications

TOP 3
Soo-Yon Rhee; W Jeffrey Fessel; Tommy F Liu; Natalia M Marlowe; Charles M Rowland; Richard Rode; Anne-Mieke Vandamme; Kristel Van Laethem; Françoise Brun Vezinet; Vincent Calvez; Jonathan Taylor; Leo Hurley; Michael Horberg; Robert W Shafer
Predictive value of HIV-1 genotypic resistance test interpretation algorithms.
Thomas J Podsadecki; Bernard C Vrijens; Eric Tousset; Richard Rode; George J Hanna
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Thomas J Podsadecki; Bernard C Vrijens; Eric Tousset; Richard Rode; George J Hanna
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Rode (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Soo-Yon Rhee; W Jeffrey Fessel; Tommy F Liu; Natalia M Marlowe; Charles M Rowland; Richard Rode; Anne-Mieke Vandamme; Kristel Van Laethem; Françoise Brun Vezinet; Vincent Calvez; Jonathan Taylor; Leo Hurley; Michael Horberg; Robert W Shafer
Predictive value of HIV-1 genotypic resistance test interpretation algorithms.
The Journal of infectious diseases 2009;200(3):453-63.
2008: Thomas J Podsadecki; Bernard C Vrijens; Eric Tousset; Richard Rode; George J Hanna
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
HIV clinical trials 2008;9(4):238-46.
2007: Thomas J Podsadecki; Bernard C Vrijens; Eric Tousset; Richard Rode; George J Hanna
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
The Journal of infectious diseases 2007;196(12):1773-8.
2007: Jean-Michel Molina; Thomas J Podsadecki; Margaret A Johnson; Aimee Wilkin; Pere Domingo; Robert Myers; Jan M Hairrell; Richard Rode; Martin S King; George J Hanna
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
AIDS research and human retroviruses 2007;23(12):1505-14.
2007: Martin S King; Richard Rode; Isabelle Cohen-Codar; Vincent Calvez; Anne-Geneviève Marcelin; George J Hanna; Dale J Kempf
Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2007;51(9):3067-74.
2006: Eduardo Sprinz; Andrade J Neto; Eduardo Bargman; Stephen L Green; Michelle P Luo; Jacquelyn R Sylte; Florence I McMillan; Kathryn R King; Richard Rode; Scott C Brun; George J Hanna; Thomas J Podsadecki
Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
HIV clinical trials 2006;7(6):291-308.
2006: Grace P S Kwong; Azra C Ghani; Richard Rode; Lucy M. A. Marshall; Benjamin J Cowling; Barbara da Silva; Christl A Donnelly; Ard I van Sighem; William Cameron; Sven A Danner; Frank de Wolf; Roy M Anderson
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
AIDS (London, England) 2006;20(15):1941-50.
2005: Neil M Ferguson; Christl A Donnelly; J Hooper; Azra C Ghani; Christophe Fraser; Lucy M. A. Marshall; Richard Rode; P Vernazza; D Lapins; S L Mayer; Roy M Anderson
Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.
Journal of the Royal Society, Interface / the Royal Society 2005;2(4):349-63.
2005: Bernard Vrijens; Els Goetghebeur; Erik de Klerk; Richard Rode; Steve Mayer; John Urquhart
Modelling the association between adherence and viral load in HIV-infected patients.
Statistics in medicine 2005;24(17):2719-31.
2005: Christl A Donnelly; Lucy M. A. Marshall; Azra C Ghani; Andrea M Le Fevre; G P Kwong; Benjamin J Cowling; Ard I van Sighem; Frank de Wolf; Richard Rode; Roy M Anderson
Gender difference in HIV-1 RNA viral loads.
HIV medicine 2005;6(3):170-8.
2005: Bernard Vrijens; Eric Tousset; Richard Rode; Richard Bertz; Steve Mayer; John Urquhart
Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.
Journal of clinical pharmacology 2005;45(4):461-7.
2003: Xavier Sáez-Llorens; Avyi Violari; Carl O Deetz; Richard Rode; Perry Gomez; Edward Handelsman; Stephen I Pelton; Octavio Ramilo; Pedro Cahn; Ellen Chadwick; Upton Allen; Stephen Arpadi; Maria Mercedes Castrejón; Renee S Heuser; Dale J Kempf; Richard Bertz; Ann F Hsu; Barry Bernstein; Cheryl L Renz; Eugene Sun
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
The Pediatric infectious disease journal 2003;22(3):216-24.
2003: Ann Hsu; Jeffrey D Isaacson; Scott C Brun; Barry Bernstein; Wayne Lam; Richard Bertz; Cheryl Foit; Karen Rynkiewicz; Bruce Richards; Martin King; Richard Rode; Dale J Kempf; G Richard Granneman; Eugene Sun
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2003;47(1):350-9.
2002: Nancy S Shulman; Andrew R Zolopa; Diane V Havlir; Ann Hsu; Cheryl Renz; Sheila Boller; Ping Jiang; Richard Rode; Joel E Gallant; Elizabeth Race; Dale J Kempf; Eugene Sun
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
Antimicrobial agents and chemotherapy 2002;46(12):3907-16.
2002: Dale J Kempf; Jeffrey D Isaacson; Martin S King; Scott C Brun; Jacquelyn Sylte; Bruce Richards; Barry Bernstein; Richard Rode; Eugene Sun
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Antiviral therapy 2002;7(3):165-74.
2001: Dale J Kempf; Jeffrey D Isaacson; Martin S King; Scott C Brun; Y Xu; K Real; Barry Bernstein; Anthony J Japour; Eugene Sun; Richard Rode
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Journal of virology 2001;75(16):7462-9.
1999: William Cameron; Anthony J Japour; Y Xu; Ann Hsu; J Mellors; C Farthing; C Cohen; D Poretz; M Markowitz; S Follansbee; Jonathan B Angel; D McMahon; D Ho; V Devanarayan; Richard Rode; M Salgo; Dale J Kempf; Richard G Granneman; JM Leonard; Eugene Sun
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
AIDS (London, England) 1999;13(2):213-24.
1998: Dale J Kempf; Richard Rode; Y Xu; Eugene Sun; ME Heath-Chiozzi; J Valdes; Anthony J Japour; S Danner; C Boucher; Akhteruzzaman Molla; JM Leonard
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.
AIDS (London, England) 1998;12(5):F9-14.
1998: William Cameron; ME Heath-Chiozzi; S Danner; C Cohen; Stephen Kravcik; C Maurath; Eugene Sun; D Henry; Richard Rode; A Potthoff; J Leonard
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
Lancet 1998;351(9102):543-9.
1990: D J Hardy; R N Swanson; Richard Rode; Kennan Marsh; N L Shipkowitz; J J Clement
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
Antimicrobial agents and chemotherapy 1990;34(7):1407-13.
1988: P B Fernandes; N Ramer; Richard Rode; L Freiberg
Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(1):73-6.
1987: C W Hanson; R Bailer; E Gade; Richard Rode; P B Fernandes
Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).
Journal of clinical microbiology 1987;25(6):1079-82.